Fasiplon
From Wikipedia, the free encyclopedia
 |
|
|---|---|
| Systematic (IUPAC) name | |
| 6-Ethyl-7-methoxy-5-methyl-2-(5-methyl-[1,2,4]oxadiazol-3-yl)-imidazo[1,2-a]pyrimidine | |
| Clinical data | |
| Pregnancy cat. | ? |
| Legal status | ? |
| Identifiers | |
| CAS number | 106100-65-6 |
| ATC code | None |
| PubChem | CID 208954 |
| ChemSpider | 181047 |
| UNII | XCA050IPGB  |
| Chemical data | |
| Formula | C13H15N5O2 |
| Mol. mass | 273.290 g/mol |
|
|
|
|
 (what is this?) (verify) |
|
Fasiplon is a nonbenzodiazepine anxiolytic drug from the imidazopyrimidine family of drugs.
Fasiplon binds strongly to benzodiazepine sites on the GABAA receptor and has similar anxiolytic effects in animals, but with less sedative or muscle relaxant action.[1] It was developed by a team at Roussel Ucla in the 1990s[2]
References [edit]
- ^ Tully WR, Gardner CR, Gillespie RJ, Westwood R (July 1991). "2-(oxadiazolyl)- and 2-(thiazolyl)imidazo[1,2-a]pyrimidines as agonists and inverse agonists at benzodiazepine receptors". Journal of Medicinal Chemistry 34 (7): 2060–7. doi:10.1021/jm00111a021. PMID 1648620.
- ^ US Patent 5869481 Anticonvulsive 1-ar(alk)ylimidazolin-2-ones and process for making
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||
